View Older Stories View More Recent Stories

May 5, 2022 08:30AM Genprex Issues Shareholder Letter and Provides 2022 Corporate Update
Apr 18, 2022 08:15AM Genprex to Participate in Upcoming Investor and Industry Conferences in April 2022
Mar 31, 2022 07:05AM Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancer
Mar 23, 2022 08:00AM Genprex to Participate in Upcoming Investor Conference in March
Mar 2, 2022 08:00AM Genprex Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
Feb 9, 2022 08:15AM Genprex to Present at Upcoming Investor Conferences Highlighting its Gene Therapies for Cancer and Diabetes
Jan 27, 2022 11:24AM Genprex (GNPX) Announces Preclinical Data Show Potential for Use of ONCOPREX Nanoparticle Delivery System in Treating Colon Cancer
Jan 27, 2022 11:23AM Preclinical Data Show Potential for Use of Genprex’s ONCOPREX® Nanoparticle Delivery System in Treating Colon Cancer
Jan 10, 2022 09:17AM Genprex to Accelerate Opening of Acclaim-1 Clinical Trial Sites for REQORSA™ Systemic Gene Therapy in Non-Small Cell Lung Cancer
Jan 5, 2022 08:00AM Genprex to Participate in January Investor and Healthcare Conferences to Highlight Company’s Gene Therapies in Cancer and Diabetes
Jan 4, 2022 08:02AM Genprex (GNPX) Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer
Jan 4, 2022 08:00AM Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer
Jan 3, 2022 08:03AM Genprex (GNPX) Granted FDA Fast Track Designation for REQORSA in Combination With Keytruda
Jan 3, 2022 08:00AM Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer
Nov 16, 2021 08:30AM Genprex to Present in November CEO Roadshow Webinar
Sep 28, 2021 06:51AM Genprex (GNPX) Announces Appointments of Mark S. Berger, M.D. as CMO and Hemant Kumar, Ph.D. as Chief Manufacturing and Technology Officer
Sep 28, 2021 06:50AM Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S. Berger, M.D. as Chief Medical Officer and Hemant Kumar, Ph.D. as Chief Manufacturing and Technology Officer
Sep 20, 2021 07:00AM Genprex to Participate in September Investor Conferences
Jul 20, 2021 08:30AM Genprex to Participate in a Monthly CEO Roadshow Webinar Series
Jun 23, 2021 08:30AM Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review
May 19, 2021 08:30AM Genprex Announces Participation in Noble Capital Markets’ Virtual Roadshow Series
May 10, 2021 08:30AM Genprex to Participate in Upcoming May Investor Conferences
May 6, 2021 09:05AM Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer
May 5, 2021 08:55AM Genprex (GNPX) Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer
May 5, 2021 08:55AM Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer
May 4, 2021 09:32AM Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer
Apr 21, 2021 08:30AM Genprex to Participate in CEO Roadshow Webinar Series
Apr 20, 2021 08:30AM Genprex to Receive Inaugural “License of the Year” Award from University of Pittsburgh Innovation Institute in Recognition of Advances Made with Gene Therapy Program in Diabetes
Apr 12, 2021 08:37AM Genprex (GNPX) Collaborators Report Positive Preclinical Data for REQORSA Immunogene Therapy in Non-Small Cell Lung Cancer at AACR
Apr 12, 2021 08:30AM Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene Therapy in Non-Small Cell Lung Cancer at the 2021 AACR Annual Meeting
Apr 5, 2021 08:30AM Genprex to Present at the 2021 Virtual Cell & Gene Meeting on the Mediterranean
Mar 30, 2021 08:32AM Genprex (GNPX) Announces Preclinical Data for TUSC2 Immunogene Therapy in Non-Small Cell Lung Cancer to Be Featured in Two Presentations at AACR
Mar 30, 2021 08:30AM Genprex Announces Preclinical Data for TUSC2 Immunogene Therapy in Non-Small Cell Lung Cancer to Be Featured in Two Presentations at the 2021 American Association for Cancer Research Annual Meeting
Mar 24, 2021 08:30AM Genprex to Present at the Spring 2021 Oncology Investor Conference on March 29
Mar 1, 2021 08:30AM Genprex to Participate in Upcoming March Investor Conferences
Feb 9, 2021 08:31AM Genprex (GNPX) Announces $25 Million Registered Direct Offering of Common Stock
Feb 9, 2021 08:30AM Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants
Feb 8, 2021 03:30PM Genprex Announces Formation of Clinical Advisory Board
Feb 4, 2021 08:30AM Genprex Recognizes World Cancer Day
Feb 1, 2021 01:33PM Genprex (GNPX) Issues Shareholder Update
Feb 1, 2021 01:30PM Genprex Issues Shareholder Letter and Provides Corporate Update
Jan 27, 2021 08:30AM Genprex to Present at the Virtual Investor Conference Small and Microcap Showcase on February 4
Jan 21, 2021 08:30AM Genprex to Present its Cutting-Edge Gene Therapies at the MoneyShow Accredited Investors Virtual Expo
Jan 14, 2021 08:30AM Genprex to Present at NobleCon17 on January 19
Jan 13, 2021 09:00AM Genprex Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer
Dec 24, 2020 01:02PM Genprex, Inc. Announces Closing Of $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Without Warrants
Dec 22, 2020 01:15PM Genprex (GNPX) Announces $12 Million Registered Direct Offering of Common Stock
Dec 22, 2020 01:15PM Genprex, Inc. Announces $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules, Without Warrants
Dec 22, 2020 09:32AM Genprex Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer
Dec 8, 2020 08:16AM Genprex Completes Manufacturing Technology Transfer for Novel Gene Therapy
View More Recent Stories View Older Stories